Key clinical point: Patients with rheumatoid arthritis (RA) showed greater clinically meaningful improvements in fatigue, sleep, and health-related quality of life (HRQoL) with tofacitinib vs. placebo over 6 months, with improvements sustained up to 12 months.
Major finding: The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) total score, Medical Outcomes Study Sleep scale (MOS-SS) Sleep Problems Index I and II scores, and Short Form-36 Health Survey (Physical/Mental Component Summary) score improved significantly with both 5 mg or 10 mg tofacitinib doses vs. placebo at months 1, 3, and 6 (all P < .05). Improvement in FACIT-F and MOS-SS scores were significantly better with 10 mg tofacitinib vs. adalimumab at 6 and 12 months (all P < .05).
Study details: This was a post hoc analysis of three phase 3 trials including 2265 patients with RA who received tofacitinib, placebo, or adalimumab.
Disclosures: This study was sponsored by Pfizer Inc. C Murray, D Gruben, and DA Gold declared being employees and stockholders of Pfizer. Some authors declared being on steering committees, boards of directors, or speakers’ bureaus or receiving consulting fees or research grants from various sources, including Pfizer.
Source: Bartlett SJ et al. The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from phase 3 trials. Arthritis Res Ther. 2022;24:83 (Apr 5). Doi: 10.1186/s13075-022-02724-x